WallStSmart

Agnico Eagle Mines Limited (AEM)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 393% more annual revenue ($58.74B vs $11.91B). AEM leads profitability with a 37.5% profit margin vs 17.4%. AZN appears more attractively valued with a PEG of 1.50. AEM earns a higher WallStSmart Score of 73/100 (B).

AEM

Strong Buy

73

out of 100

Grade: B

Growth: 8.0Profit: 9.0Value: 7.3Quality: 8.5
Piotroski: 6/9Altman Z: 2.83

AZN

Strong Buy

66

out of 100

Grade: B-

Growth: 6.7Profit: 8.0Value: 10.0Quality: 6.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AEMUndervalued (+47.7%)

Margin of Safety

+47.7%

Fair Value

$415.12

Current Price

$192.07

$223.05 discount

UndervaluedFair: $415.12Overvalued
AZNUndervalued (+32.8%)

Margin of Safety

+32.8%

Fair Value

$306.07

Current Price

$185.78

$120.29 discount

UndervaluedFair: $306.07Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AEM6 strengths · Avg: 9.5/10
Profit MarginProfitability
37.5%10/10

Keeps 38 of every $100 in revenue as profit

Operating MarginProfitability
64.7%10/10

Strong operational efficiency at 64.7%

Revenue GrowthGrowth
60.3%10/10

Revenue surging 60.3% year-over-year

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Market CapQuality
$89.62B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.30B8/10

Generating 1.3B in free cash flow

AZN5 strengths · Avg: 9.0/10
Market CapQuality
$284.63B10/10

Mega-cap, among the largest globally

EPS GrowthGrowth
53.9%10/10

Earnings expanding 53.9% YoY

Return on EquityProfitability
22.8%9/10

Every $100 of equity generates 23 in profit

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$1.38B8/10

Generating 1.4B in free cash flow

Areas to Watch

AEM2 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.0%4/10

2.0% earnings growth

PEG RatioValuation
28.152/10

Expensive relative to growth rate

AZN3 concerns · Avg: 3.3/10
P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.1%4/10

4.1% revenue growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AEM

The strongest argument for AEM centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 37.5% and operating margin at 64.7%. Revenue growth of 60.3% demonstrates continued momentum.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.

Bear Case : AEM

The primary concerns for AEM are EPS Growth, PEG Ratio.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

AEM profiles as a growth stock while AZN is a value play — different risk/reward profiles.

AEM carries more volatility with a beta of 0.61 — expect wider price swings.

AEM is growing revenue faster at 60.3% — sustainability is the question.

AZN generates stronger free cash flow (1.4B), providing more financial flexibility.

Bottom Line

AEM scores higher overall (73/100 vs 66/100), backed by strong 37.5% margins and 60.3% revenue growth. AZN offers better value entry with a 32.8% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agnico Eagle Mines Limited

BASIC MATERIALS · GOLD · USA

Agnico Eagle Mines Limited is engaged in the exploration, development and production of mineral properties in Canada, Sweden and Finland. The company is headquartered in Toronto, Canada.

Visit Website →

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?